Last week’s Liothyronine judgment in the UK’s Competition Appeal Tribunal (CAT) is essential reading for antitrust practitioners. The CAT upheld the CMA finding of an abuse of dominance but reduced the total fine from £101m to £84m. Liothyronine is one of several excessive pricing cases the CMA has brought in recent years following concerns about … Continue reading CAT’s Liothyronine judgment is notable beyond excessive pricing cases →